USA – BioNeex, a NYC-based provider of a biopharmaceutical industry’s research and development (R&D) business development platform, raised $500K in Seed funding.
The round was led by biopharma industry leaders, including former executives at Pfizer and Amgen.The company intends to use the funds for product development, including to enhance the user experience for BioNeex platform members. Led by Dr. Smbat Rafayelyan, Founder and CEO, and Edgar Marukyan, Chief Technology Officer, BioNeex provides a R&D business development platform for the biopharmaceutical industry, which is a marketplace where biotech and biopharma companies, along with venture capital firms come together to directly facilitate licensing and co-development partnerships for preclinical and clinical-stage drug candidates, and investment deals. BioNeex enables potential licensing and co-development partners and investors access to the up-to-date information from drug candidate developers, and to contact them directly. Commenting on the news, Smbat Rafayelyan said: “Their investment in BioNeex will help us continue to provide new products, services and platform enhancements that improve how drug development companies, potential partners and investors interact via the BioNeex marketplace.“16/02/2024
